SCHEMBL23218259

SCHEMBL23218259

COC(=O)Cc1cccc(OCc2cc3cccc(-c4cccc(CN)c4)c3o2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 5/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
ESR1 P03372 2/20 0.41
THRA P10827 2/20 0.41
THRB P10828 2/20 0.41
VDR P11473 2/20 0.41
RXRA P19793 2/20 0.41
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
ESR2 Q92731 2/20 0.41
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GPR52 Q9Y2T5 1/20 0.37
MAOB P27338 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218757 0.89 CFD (0.53) CFDVDRPPARDPLGPLAU
SCHEMBL23218055 0.81 ESR1 (0.41) PDE4APDE4BPDE4CPDE4DESR1
SCHEMBL29852945 0.80 CFD (0.47) CFDPDE4APDE4BPDE4CPDE4D
SCHEMBL23218430 0.80 CFD (0.47) CFDPDE4APDE4BPDE4CPDE4D
SCHEMBL29853190 0.76 CFD (0.55) CFDPLGPLAUF11KLKB1
SCHEMBL23219109 0.76 CFD (0.55) CFDPLGPLAUF11KLKB1
SCHEMBL29593125 0.76 CFD (0.66) CFDPLGPLAUF11KLKB1
SCHEMBL23219103 0.76 CFD (0.66) CFDPLGPLAUF11KLKB1
SCHEMBL23219094 0.74 CFD (0.60) CFDPLGPLAUF11KLKB1
SCHEMBL23218442 0.73 CFD (0.46) CFDPLGPLAUF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PDE4A 4455/4885PDE4B 4512/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PDE4A 3229/4885PDE4B 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.